| HOME >> BIOLOGY >> TECHNOLOGY |
application for the additional use of the PROCLEIX ULTRIO assay to
screen donated blood for hepatitis B virus (HBV). The FDA approved the
assay to screen donated blood for HIV-1 and hepatitis C virus in late
2006. The Company is seeking approval to use the assay to screen for
HBV on both its semi-automated instrument platform and on the fully
automated, high-throughput TIGRIS system.
-- HPV Clinical Trial Begins. On March 31, Gen-Probe announced that the
Company had begun a pivotal U.S. clinical trial of its investigational
APTIMA assay to detect HPV, which causes cervical cancer. The
investigational APTIMA HPV assay is an amplified nucleic acid test that
is designed to detect 14 high-risk HPV types that are associated with
cervical cancer. More specifically, the assay is designed to detect two
messenger RNAs (mRNAs), E6 and E7, which are produced in higher amounts
when HPV infections progress toward cervical cancer. Gen-Probe expects
to enroll approximately 7,000 women in the study. Actual enrollment,
however, may vary based on the prevalence of cervical disease among
women in the trial. The trial enrollment and testing are expected to
take approximately two years.
-- Two PCA3 Studies Published. The leading peer-reviewed Journal of
Urology(R) published two important articles that the Company believes
illustrate the value of Gen-Probe's prostate cancer marker PCA3. In
the first article, "PCA3: A Molecular Urine Assay for Predicting
Prostate Biopsy Outcome" (Volume 179, Issue 4, Pages 1587-1592,
April 2008), researchers from the Urological Sciences Research
Foundation, The Johns Hopkins University, the University of Washington,
DiagnoCure and Gen-Probe conclude that PCA3 is
'/>"/>
| SOURCE Gen-Probe Incorporated Copyright©2008 PR Newswire. All rights reserved |